Adjunctive Intravitreal Triamcinolone Acetonide for Exudative Retinal Detachment in Coats Disease

Area of Science:

• Ophthalmology
• Retinal Diseases
• Medical Treatments

Background:

• Coats disease is a rare condition causing abnormal blood vessel development in the retina.
• Advanced stages (stage 3+) often involve exudative retinal detachment (ERD) and significant subretinal fluid (SRF).
• Current treatments aim to reduce SRF and facilitate retinal reattachment.

Purpose of the Study:

• To evaluate intravitreal triamcinolone acetonide (IVTA) as an adjunctive therapy for advanced Coats disease (stage 3 or higher).
• To assess IVTA's efficacy in reducing SRF and facilitating ablative therapy.
• To determine if IVTA can help avoid surgical drainage of SRF.

Main Methods:

• Retrospective review of 17 patients with advanced Coats disease treated with IVTA.
• IVTA was administered to decrease SRF and support retinal ablative therapy.
• Primary outcomes measured were SRF resolution and avoidance of surgical drainage.

Main Results:

• Complete SRF resolution was achieved in 76.4% (13/17 eyes) after a mean of 1.3 IVTA injections.
• None of the eyes with complete SRF resolution required surgical drainage.
• SRF persisted in 4 eyes with bullous ERD, with 2 requiring surgical drainage (P = .015).
• Cataract developed in 70.5% of eyes; no significant increase in intraocular pressure was noted.

Conclusions:

• IVTA is a valuable adjunctive therapy for managing SRF in advanced Coats disease.
• IVTA can potentially obviate the need for surgical SRF drainage, especially in non-bullous ERD.
• Further research may explore optimal IVTA protocols for Coats disease management.